Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 2a, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of AKR-001 in Subjects With Nonalcoholic Steatohepatitis (NASH)

Next Previous
Trial Profile

Phase 2a, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of AKR-001 in Subjects With Nonalcoholic Steatohepatitis (NASH)

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 16 Oct 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs AKR-001 (Primary)
  • Indications Non-alcoholic steatohepatitis
  • Focus Therapeutic Use
  • Acronyms BALANCED
  • Sponsors Akero Therapeutics

    • Most Recent Events

    • 03 Oct 2019 According to an Akero Therapeutics media release, Akero Therapeutics and InSphero AG today announced that Akero has selected InSpheros 3D InSight Human Liver Disease Platform to characterize the physiological effects of AKR-001 in different types of liver cells.The company will now evaluate AKR-001s effects on human liver cells to help contextualize results from this ongoing Phase 2a clinical trial.
    • 12 Aug 2019 According to an Akero Therapeutics media release, collection of data for the primary endpoint is expected to be completed in the first quarter of 2020, and collection of all study data, including repeat liver biopsies, is expected to be completed in the second quarter of 2020. The company will report results primary endpoint in the first quarter of 2020 and full study results in the second quarter of 2020.
    • 02 Jul 2019 According to an Akero Therapeutics media release, results are expected n the first half of 2020.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Legal

Back to top